Pharma Mar
PHM.MCPHM.MC · Stock Price
Historical price data
Overview
Pharma Mar's mission is to discover and develop novel cancer therapies derived from the chemical diversity of marine organisms. Its key achievement is the successful global commercialization of Yondelis® (trabectedin), a first-in-class marine-derived drug approved for soft tissue sarcoma and ovarian cancer, validating its unique platform. The company's strategy focuses on leveraging its proprietary marine biology and chemistry expertise to advance a deep pipeline of drug candidates, while exploring new indications and combinations for its existing assets. This integrated approach, from discovery to manufacturing and commercialization, aims to deliver long-term growth in the oncology market.
Technology Platform
Proprietary, integrated platform for discovering and developing novel anti-cancer compounds from marine organisms, encompassing sustainable sourcing, bioassay-guided isolation, structural characterization, total synthesis, and translational development.
Pipeline
1| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Ferric carboxymaltose + ferrous glycine sulphate | Postoperative Anemia | Approved |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Pharma Mar competes with large pharmaceutical and biotech firms in oncology, but its marine-derived compounds offer unique mechanisms of action that can differentiate them in specific tumor types. For Yondelis and Zepzelca, competition includes standard chemotherapies and, increasingly, targeted therapies and immunotherapies. Its sustainable marine platform and deep expertise in this niche create a significant barrier to entry for competitors.